TITAN PHARMACEUTICALS Initiates Phase II Study of Pivanex in Non-Small Cell Lung Cancer.SOUTH SAN FRANCISCO South San Francisco, city (1990 pop. 54,312), San Mateo co., W Calif.; inc. 1908. South San Francisco has several industrial parks; its manufactures include medical supplies and equipment, foods, paint, paper products, consumer goods, and clothing. , Calif.--(BW HealthWire)--July 22, 1998--TITAN PHARMACEUTICALS, INC. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : TTNP, TTNPU and TTNPW) announced today that it has initiated a multicenter Phase II study of its small molecule anti-cancer agent, Pivanex(tm), in patients with refractory stage III and IV non-small cell lung cancer Lung Cancer, Non-Small Cell Definition Non-small cell lung cancer (NSCLC) is a disease in which the cells of the lung tissues grow uncontrollably and form tumors. Description There are two kinds of lung cancers, primary and secondary. . The study may enroll up to approximately 200 patients and will be performed in two stages. In the first stage, 36 patients will be enrolled. If a sufficient number of clinical responses are seen, as defined in the study protocol, an additional 160 patients will be enrolled in the second stage of the study. Lung cancer is a leading cause of cancer related mortality in both men and women in the United States. An estimated 171,000 new cases of lung cancer will be diagnosed in the U.S. in 1998. Approximately 80 percent of the cases will be non-small cell lung cancer, and over 70 percent of patients will have advanced disease at the time of diagnosis. Pivanex(tm) has demonstrated significant anti-cancer activity in numerous laboratory and animal models, and Phase I clinical testing to date has demonstrated lack of serious dose limiting side effects often seen with conventional chemotherapy. Titan Pharmaceuticals, Inc. is a biopharmaceutical company developing proprietary therapeutics for the treatment of cancer, central nervous system disorders Nervous system disorders A satisfactory classification of diseases of the nervous system should include not only the type of reaction (congenital malformation, infection, trauma, neoplasm, vascular diseases, and degenerative, metabolic, toxic, or deficiency , and other serious and life-threatening diseases. "Safe Harbor" Statement under the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. The statements which are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties including, but not limited to, the results of research and development efforts, the results of pre-clinical and clinical testing, the effect of regulation by the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. and other agencies, the impact of competitive products, product development, commercialization and technological difficulties, and other risks detailed in the Company's Securities and Exchange Commission filings. CONTACT: Company Contact: Titan Pharmaceuticals, Inc. Louis R. Bucalo, M.D. CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. & President (650) 244-4990 or Investor Contact: Lippert/Heilshorn & Associates, Inc. Keith Lippert (keith@lhai.com) (212) 838-3777 Bruce Voss (bruce@lhai.com) (310) 575-4848 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion